Recognition of viral nucleic acids leads to type I and type III IFN gene expression and activation of host antiviral responses. At present, type III IFN genes are the least well-characterized IFN types. Here, we demonstrate that the p38 MAPK signaling pathway is involved in regulating IFN-l1 gene expression in response to various types of RNA molecules in human moDCs. Inhibition of p38 MAPK strongly reduced IFN gene expression, and overexpression of p38a MAPK enhanced IFN-l1 gene expression in RNA-stimulated moDCs. The regulation of IFN gene expression by p38 MAPK signaling was independent of protein synthesis and thus, a direct result of RNA stimulation. Moreover, the RIG-I/MDA5-MAVS-IRF3 pathway was required for p38a MAPK to up-regulate IFN-l1 promoter activation, whereas the MyD88-IRF7 pathway was not needed, and the regulation was not involved directly in IRF7-dependent IFN-a1 gene expression. The stimulatory effect of p38a MAPK on IFN-l1 mRNA expression in human moDCs did not take place directly via the activating TBK1/IKK« complex, but rather, it occurred through some other parallel pathways. Furthermore, mutations in ISRE and NF-kB binding sites in the promoter region of the IFN-l1 gene led to a significant reduction in p38a MAPK-mediated IFN responses after RNA stimulation. Altogether, our data suggest that the p38a MAPK pathway is linked with RLR signaling pathways and regulates the expression of early IFN genes after RNA stimulation cooperatively with IRF3 and NF-kB to induce antiviral responses further.
Introduction
Innate immune responses constitute the first-line defense system against invading microbial pathogens, and they also play an essential role in regulating antigen-specific adaptive-immune responses. The first step in the activation of innate immune responses is the recognition of pathogen-associated molecular patterns by PRRs [1] . The IFN system, including type I and type III IFN, is activated as a host response to viral infection, and it forms an important part of innate antiviral responses by interfering directly with the replication of viruses and activating downstream IFN-stimulated genes to elicit subsequent antiviral responses [2] [3] [4] [5] . As sentinel cells of the host, DCs are the key mediators linking innate and adaptive immunity. They are professional APCs, playing a pivotal role in initiation, regulation, and maintenance of innate and antigen-specific adaptiveimmune responses against viruses [6] . Human DCs express multiple RNA-sensing PRRs that recognize viral genomic RNA or RNA replication intermediates during infection [7] . RLRs, such as RIG-I and MDA5, reside in the cytoplasm, where they preferentially recognize uncapped RNA molecules containing 59-triphosphate moieties and base-paired regions or long dsRNAs, respectively [8] [9] [10] [11] [12] . In contrast to RLRs, TLR3 senses viral dsRNA on the plasma membrane or in endosomes, depending on the cell type, whereas TLR7 and TLR8 sense ssRNA in endosomes [13, 14] . Upon binding with RNAs, RLRs and TLRs activate their downstream signaling pathways via different adaptors.
Mitochondria-associated adaptor molecule IFN-b promoter stimulator 1 (also called MAVS, Cardif, or virus-induced signaling adaptor) is recruited by activated RIG-I or MDA5 [15] [16] [17] [18] , whereas TRIF is recruited by TLR3 activation. In addition, the adaptor protein MyD88 is mediating TLR7-and TLR8-dependent signaling [19] . The stimulation of both RLR and TLR signaling pathways results in the activation of different transcription factors, such as NF-kB and IRF3 and -7, leading to the expression of IFN genes and activation of subsequent antiviral responses [14, [20] [21] [22] [23] .
MAPKs are ubiquitously expressed serine/threonine kinases that are engaged in regulating multiple cellular functions, including gene expression, cell proliferation, differentiation, and apoptosis [24] . The MAPK family includes 3 major groups: 1) ERKs, which are stimulated by growth factors and mainly regulate cell proliferation, 2) JNKs, and 3) p38 MAPKs, which are activated by cytokines and cell stress and mediate cellular stress responses and apoptosis [25] [26] [27] [28] . The p38 MAPK family consists of 4 isoforms of p38 kinases: 1) p38a [29] , 2) p38b [30] , 3) p38d [31] and 4) p38g [32] , among which p38a MAPK is ubiquitously expressed at high levels in almost all cell types [33] . Moreover, previous studies have shown that the p38 MAPK pathway is activated by type I IFNs, and it is also involved in regulating type I IFN-dependent antiviral responses [34, 35] .
Activation of IFN responses is regulated by at least 3 groups of transcription factors: 1) ATF/c-jun, 2) IRFs, and 3) NF-kB. They bind to specific sites on promoters upstream of IFN genes and cooperatively activate the transcription [36] . The promoter regions of all type I and type III IFN genes contain PRDI/III-like motifs, which function as IRF-specific binding sites, indicating that IRFs play an important role in transcriptional regulation of type I and III IFN genes. Among 9 IRF family members, IRF3 and IRF7 are essential for regulating IFN gene expression [37] [38] [39] . Besides PRDI/III-like motifs, the promoter regions of IFN-b, IFNl1, and IFN-l3 genes also contain a NF-kB-binding motif, suggesting that these genes are regulated by IRFs and NF-kB [40] .
The mechanism of induction and regulation of type I IFN (IFN-a/b) signaling have been investigated extensively during the last decades. Our previous study also showed that RNAs of different sizes and forms induce differential IFN gene expression via different signaling pathways in human moDCs [41] . The divergent cellular signaling pathways activated by various types of RNAs may lead to differential activation of transcription factors and IFN promoters. Relatively little is known about the mechanisms by which signaling pathways, apart from those leading to the activation of IRFs and NF-kB, are involved in regulating IFN gene expression. Moreover, less attention has been paid to the structure of promoter regions of type III IFN genes, such as IFN-l1. In the current study, by use of a pharmacological approach to inhibit different signaling pathways, we show that several signaling pathways are involved in regulating IFN-l1 gene expression after stimulation with different types of RNAs in human moDCs. Furthermore, with the experimental approach of nucleofection of the p38a MAPK expression plasmid in human moDCs and overexpression of p38a MAPK or the dnp38 MAPK in HEK293 cells, our study strongly suggests that p38a MAPK positively regulates the induction of the IFN-l1 gene. We also obtained evidence that the RIG-I/MDA5-MAVS-IRF3 signaling pathway but not the MyD88-IRF7 pathway is essential for IFN gene regulation by p38a MAPK. Moreover, p38a MAPK appears to regulate IFN gene expression via a pathway apart from the activation of TBK1/IKKe. With the use of mouse 3T3 IRF3/IRF7 and NF-kB KO cells, we observed that these transcription factors are essential in regulating Ifn-b1 gene expression, and overexpression of p38a MAPK could not compensate for the lack of IRFs or NF-kB transcription factors. The DNA affinity-binding assay in human moDCs and the promoter mutation assay in HEK cells further confirmed that ISRE and NF-kB1 binding sites of the IFN-l1 promoter are essential for p38 MAPK to regulate IFN-l1 gene expression. Altogether, our data suggest that p38a MAPK positively regulates the induction of the IFN-l1 gene cooperatively with IRF3 or NF-kB transcription factors in RNA-stimulated human moDCs.
MATERIALS AND METHODS

Cell cultures
The HEK293 cell line (ATCC CLR 1573; American Type Culture Collection, Manassas, VA, USA) was maintained with continuous growth in Eagle's MEM (Sigma-Aldrich, St. Louis, MO, USA).
The primary WT and Irf3 ) 3T3 cell lines were generated from E12.5-14.5 embryos and maintained as described previously [42] . Primary MEFs were immortalized by a rigorous passaging protocol to obtain WT and IRF3/7 KO 3T3 cell lines. The MEFs and 3T3 cell lines were maintained with continuous growth in DMEM (Sigma-Aldrich).
Human primary monocytes were purified from freshly collected, leukocyterich buffy coats, obtained from healthy blood donors (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland), as described previously [43] . Monocytes were differentiated into immature DCs for 6 d in the presence of 10 ng/ml human rGM-CSF (BioSource International, Camarillo, CA, USA), and 20 ng/ml human rIL-4 (R&D Systems, Minneapolis, MN, USA) in RPMI-1640 medium.
All media were supplemented with 0.6 mg/ml penicillin, 60 mg/ml streptomycin, 2 mM L-glutamine, 20 mM HEPES, and 10% FCS (Integro, Englewood, CO, USA). All cells were maintained at 37°C in a humidified atmosphere in the presence of 5% CO 2 .
RNA preparations
Enzymatic synthesis of ssRNA and dsRNA molecules. ssRNAs and dsRNAs were produced by in vitro transcription and replication with bacteriophage T7 DNA-dependent RNA polymerase and bacteriophage f6 RNA-dependent RNA polymerase, as described previously [41] . Enzymatically synthesized ssRNA and dsRNA molecules were purified with TRIzol (Invitrogen, Carlsbad, CA, USA)/chloroform (5:1) extraction, followed by preparative agarose gel electrophoresis and precipitation with 3 M sodium acetate (88 nt RNAs) or stepwise lithium chloride precipitation (1800 nt RNAs). All RNAs were washed with 70% ethanol, dissolved in sterile water, and precipitated with 0.75 M NH 4 Ac-70% ethanol. The pellets were suspended in sterile water and desalted with NAP-5 columns (GE Healthcare, Pittsburgh, PA, USA) before HPLC purification (Gen-Pak FAX; Waters, Milford, MA, USA).
H3N2 IAV viral RNAs. IAV/Beijing/353/89 virus was concentrated by sedimentation though a 30% sucrose cushion by ultracentrifugation at 26,000 rpm in an SW32 rotor for 90 min (Beckman Coulter, Brea, CA, USA). Viral RNA was isolated from virions by use of the QIAmp viral RNA extraction kit (Qiagen, Valencia, CA, USA).
RNAs isolated from H3N2 IAV-infected moDCs. moDCs from 4 different blood donors were infected separately with H3N2 IAV. The infected moDCs from different blood donors were harvested and pooled, and total cellular RNA was isolated by use of the RNeasy Mini Kit (Qiagen), including DNase digestion (RNase-free DNase kit; Qiagen).
Expression plasmid of p38a MAPK, dnp38 MAPK, and IFN-l1 promoter mutants
The cDNA encoding for p38a MAPK was amplified from total cellular RNA isolated from human moDCs and cloned into the BamHI site of the pcDNA3.1(+) expression vector by use of primers (upstream) 59 TCGGGATCCATGTCTCAG-GAGAGGCCCACGT 39 and (downstream) 59 TCGGGATCCTTATCAGGACTC-CATCTCTTCTTGGTC 39 (BamHI site underlined; initiation codon in bold). This construct served as the template to generate further the plasmid of dnp38 MAPK by replacing threonine 180 and tyrosine 182 with alanine and phenylalanine, respectively. The oligonucleotides used to create the dnp38 MAPK construct are 59-CAGATGATGAAATGGCAGGCTTCGTGGCCACTAGG-39 and 59-CCTAGT-GGCCACGAAGCCTGCCATTTCATCATCTG-39. Mutations were incorporated by use of the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA).
Plasmid pGL3-IFN-l1-luc [40] was applied as a template in the generation of the single-site mutations at the ISRE, NF-kB1, or NF-kB2 sites of the IFN-l1 promoter region. The construct harboring the mutation at the ISRE site of the IFN-l1 promoter region was used further as a template to generate an ISRE/ NF-kB1 double mutant, in which the ISRE and NF-kB1 sites were mutated. The oligonucleotides used to generate the promoter mutants are described elsewhere [44] . Mutations were incorporated by use of the QuikChange SiteDirected Mutagenesis Kit. All plasmids were maintained and propagated in Escherichia coli strain DH5a.
Stimulation of cells with RNA molecules moDC stimulations. All experiments were performed with moDCs obtained from 4 blood donors, and the cells were stimulated separately. Cells were first treated with different pharmacological signaling inhibitors (10 mM) or CHX (10 mg/ml), 0.5 h before RNA transfection. Enzymatically synthesized RNAs, viral RNAs isolated from H3N2 IAV virions, or RNAs isolated from H3N2 IAVinfected moDCs (50 ng/ml) were transfected with Lipofectamine 2000 (Invitrogen) into moDCs, according to the manufacturer's instructions. Four hours after transfection, cells from different donors were collected and pooled. As there is a considerable individual variation in the responses in different blood donors (see Supplemental Fig. 2C 
Nucleofection in moDCs
Monocytes were differentiated into immature DCs for 6 d in the presence of 10 ng/ml human rGM-CSF (BioSource International) and 20 ng/ml human rIL-4 (R&D Systems) in RPMI-1640 medium, as described above. Cells (2 3 10 6 ) were then collected and resuspended in 100 ml nucleofector solution and combined with 5 mg plasmid, followed by the nucleofection, according to the manual of the nucleofector kit (Amaxa Human Dendritic Cell Nucleofector kit; Lonza, Cologne, Germany). Transfected cells were then plated onto a 12-well plate and incubated in a humidified 37°C/5% CO 2 incubator for a further 20 h, followed by RNA stimulation. 
Luciferase reporter assay
Western blot analysis
Whole-cell lysates were prepared from moDCs, derived from 4 pooled donors or from HEK293 cells in Passive Lysis buffer of the Dual Luciferase assay kit (Promega) containing 1 mM Na 3 VO 4 . Protein aliquots of whole-cell lysates (30 mg) were separated on 10% SDS polyacrylamide gels by use of the Laemmli buffer system [46] . Proteins were transferred onto Immobilon-P membranes, followed by blocking with 5% milk in PBS (or in TBS for cellsignaling anti-phospho-protein antibodies). Rabbit anti-IRF3 antibody, guinea pig anti-RIG-I, and anti-IRF7 were used, as described previously [41, 47] . Antibodies against the phosphorylated forms of IRF3 (Ser396), the phosphorylated forms of p38 MAPK (T180/Y182), TRIF, and p38 MAPK were from Cell Signaling Technology (Beverly, MA, USA). Rabbit anti-MyD88 and anti-MAVS antibodies were prepared by immunizing rabbits with baculovirusexpressed, preparative SDS-PAGE (Bio-Rad Laboratories, Hercules, CA, USA)-purified proteins (4 immunizations, 20 mg/immunization). HRP-conjugated goat anti-rabbit or rabbit anti-guinea pig antibodies (DakoCytomation, Carpinteria, CA, USA) were used in secondary staining. Antibody binding was visualized by the ECL system on HyperMax films (GE Healthcare). Software ImageJ was used for densitometry analysis of Western blots.
DNA affinity-binding assay
dsRNA-induced activation of transcription factors was studied by use of the DNA affinity-binding method, as described previously [47] . The used, putative ISRE and NF-kB1 binding-site oligonucleotide sequences from the IFN-l1
promoters were described elsewhere [40, 47] . The bound proteins were separated on SDS-PAGE and visualized by use of specific antibodies against the phosphorylated form of IRF3 (Ser396) and against p65 and p50 proteins (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical analysis
All experiments are presented as means 6 SD. Statistical analyses were performed by use of unpaired, two-tailed Student's t-test. The differences were considered to be statistically significant when P , 0.05.
RESULTS
Effects of MAPK, PI3K, and NF-kB inhibitors on RNA-induced IFN-l1 gene expression in human moDCs
In human moDCs, different types of RNAs can induce type III IFN gene expression, such as IFN-l1, through multiple PRR signaling pathways with different efficiency [41] . To investigate further the role of multiple signaling pathways in regulating IFNl1 gene expression after RNA stimulation, we analyzed the role of several pharmacological inhibitors on the key component of selected signaling pathways. moDCs were transfected with various types of enzymatically synthesized ds/ssRNAs in the presence or absence of inhibitors PD98059 (ERK inhibitor), SB202190 (p38 MAPK inhibitor), SP600125 (JNK inhibitor), Ly294002 (PI3K inhibitor), and pyrrolidine dithiocarbamate (NF-kB inhibitor).
The expression of IFN-l1, IFN-b, and IFN-a1 was studied at the mRNA level at 4 h after RNA stimulation ( Fig. 1A and Supplemental Fig. 1A and B). Consistent with our previous study [41] , short dsRNA and ssRNA molecules induced higher levels of IFN-l1 mRNA expression compared with long RNA molecules. We observed that all studied inhibitors suppressed the upregulation of IFN-l1 mRNA after RNA stimulation to a varying degree. Notably, the production of IFN-l1 mRNA was most dramatically and significantly inhibited by the p38 MAPK inhibitor, SB202190 ( Fig. 1A and Supplemental Fig. 2B ), and this inhibition was clearly dose dependent (Supplemental Fig. 2A ). Similar results were seen with the IFN-b and IFN-a1 genes (Supplemental Fig. 1A and B). The explicit inhibition of IFN-l1 gene expression by the p38 MAPK inhibitor, SB202190 was also evident in cells from all different blood donors that were analyzed separately (Supplemental Fig. 2C ). To study the ability of real viral RNA to induce IFN-l1 mRNA expression, viral RNA isolated from purified IAV virions or RNA isolated from IAVinfected moDCs was used to stimulate moDCs, in the presence or absence of signaling inhibitors ( p38 MAPK is regulating IFN-l1 gene expression in RNA-stimulated human moDCs
To investigate further the role of p38 MAPK in regulating IFN-l1 gene expression in RNA-stimulated human moDCs, we analyzed the time-dependent kinetics of 2 p38 MAPK inhibitors SB203580 and SB202190 on regulating IFN-l1 mRNA expression. moDCs were transfected with 88 bp dsRNAs in the presence or absence of inhibitors, and IFN-l1 mRNA expression was studied at 1, 2, 4, and 8 h after RNA stimulation. Both inhibitors suppressed the up-regulation of IFN-l1 mRNA expression in a similar fashion, and inhibition was already observed at 2 h after RNA stimulation, reaching the highest level at 4 h and reducing within 8 h after stimulation ( Fig. 2A) .
It is well known that multiple IFN types are regulated by IRF3 [5, 40] . Next, we investigated whether the p38 MAPK was involved in dsRNA-induced phosphorylation of IRF3 in human moDCs. The expression of phosphorylated IRF3, phosphorylated p38, total cellular IRF3, and p38 was analyzed by Western blotting at different time-points after 88 bp dsRNA stimulation in the presence or absence of SB203580 and SB202190 (Fig. 2B) . Consistent with the kinetics of IFN-l1 mRNA expression ( Fig.  2A) , the amount of phosphorylated IRF3 increased up to the 8 h time-point in the absence of p38 MAPK inhibitors (Fig. 2B) . Neither one of the inhibitors decreased the phosphorylation of IRF3, whereas the presence of p38 inhibitors led to increased phosphorylation level of p38 at 4 h and 8 h in RNA-stimulated and unstimulated moDCs (Fig. 2B) . The total amount of IRF3 and p38 remained relatively constant.
As off-target effects of p38 MAPK inhibitors have been described in some studies [48, 49] , we investigated whether p38 MAPK is involved in regulating IFN-l1 mRNA expression in human moDCs by nucleofection expression of cDNA for the human p38a isoform in human moDCs. Among the 4 isoforms of p38 MAPK, p38a MAPK is the one that is ubiquitously expressed in different cell types [33] and is involved in regulating IFN signaling [35] . The overexpression of p38a MAPK increased IFN-l1 mRNA expression in RNA-stimulated moDCs (Fig. 2C) . Western blot analysis showed that the protein amount of Figure 2 . The role of p38 MAPK in regulating IFN-l1 mRNA expression in short dsRNA-stimulated human moDCs. moDCs from 4 different blood donors were grown separately on 24-well plates. (A) Cells remained untreated or were pretreated with p38 MAPK inhibitor SB203580 or SB202190 (10 mM), 0.5 h before transfection with 88 bp dsRNA (50 ng/ml). Cells were collected at indicated time-points after RNA transfection, total cellular RNA was isolated, and IFN-l1 mRNA expression was determined by quantitative RT-PCR. (C) IFN-l1 mRNA expression in short dsRNA-stimulated human moDCs after nucleofection of p38a MAPK. Cells (2 3 10 6 cells/well) were un-nucleofected or nucleofected with an empty pcDNA or a p38a MAPKexpressing plasmid (5 mg/well), 20 h before transfection of 88 bp dsRNA (50 ng/ml); cells were collected 4 h after RNA transfection; total cellular RNA was isolated; and relative expression of IFN-l1 mRNA was measured by quantitative RT-PCR. The values were normalized against b-ACTIN, and relative IFN-l1 mRNA levels were calculated with the DDCt method by use of untreated cells as a calibrator. The means (6SD) of 3 parallel determinations are shown. Data are representative of 3 individual experiments. Results were considered statistically significant when *P , 0.05 compared with uninhibited and pcDNA-transfected cellular samples, respectively (boxed bars). (B and D) Western blot analysis for the expression of phospho (P)-IRF3 and total IRF3 protein and phospho (P)-p38 MAPK and total p38 protein in short dsRNA-stimulated human moDCs. Cells were collected at 1, 2, 4, and 8 h after RNA transfection, with or without the presence of p38 MAPK inhibitors (B) or 4 h after RNA transfection (D), with or without the nucleofection of the p38 MAPK expression plasmid, and whole-cell lysates were prepared. Cellular proteins (30 mg/lane) were separated on 10% SDS-PAGE, followed by electrophoretic transfer of the proteins onto PVDF membranes and detection of the transferred proteins by antibodies that are specific for phospho-IRF3, IRF3, phospho-p38, and p38, as indicated. The data of 1 representative experiment of 3 independent experiments are shown. phosphorylated and unphosphorylated p38 MAPK slightly increased after nucleofection of p38a MAPK in moDCs, and the phosphorylation level of IRF3 was increased after 88 bp dsRNA stimulation, whereas it remained approximately the same after p38a MAPK overexpression (Fig. 2D) .
dsRNA-induced IFN-l1 gene expression is regulated by p38 MAPK in the absence of protein synthesis
To analyze whether ongoing protein synthesis was needed for RNA-induced IFN-l1 gene expression via the p38 MAPK pathway, we used CHX to block protein synthesis during the stimulation. As CHX is toxic to the cells, we selected a relatively early time-point of 3 h for our stimulation experiment. Human moDCs were stimulated with 88 bp dsRNA, and IFN-l1 mRNA expression was analyzed by quantitative PCR (Fig. 3) . We found that 88 bp dsRNA was capable of inducing IFN-l1 mRNA expression in the presence and absence of CHX, and CHX did not affect SB202190-mediated inhibition of IFN-l1 expression, indicating that the p38 MAPK pathway is involved directly in the regulation of IFN-l1 gene expression. Similar results were also obtained for the IFN-a1 gene (Supplemental Fig. 3 ). However, CHX treatment led to superinduction of IFN-a1 mRNA expression (Supplemental Fig. 3 ), which is a previously identified phenomenon related to the accumulation of mRNAs as a result of blocking protein synthesis or of removal of a negative-feedback mechanism of cytokine mRNA degradation.
The p38 MAPK signaling pathway regulates IFN-l1 gene expression through RLR/TLR3 signaling pathways in dsRNA-stimulated HEK293 cells
It is well known that RLRs and TLR3 are the main cellular dsRNA-recognizing receptors that activate IFN gene expression and antiviral responses [14, 50] . Having seen that the p38 MAPK signaling pathway is involved in regulating IFN-l1 gene expression in human moDCs after RNA stimulation (Figs. 1 and 2 and Supplemental Figs. 1 and 2) , we transiently expressed different RLR/TLR receptors in HEK293 cells to identify which signaling pathways are positively regulated by p38 MAPK. For these stimulation experiments, the expression construct of p38a MAPK and dnp38 together with 88 bp dsRNA was used to study the role of p38a MAPK in dsRNA-regulated IFN gene expression. In RIG-I-, MDA5-, and TLR3-overexpressing HEK293 cells, SB202190 inhibited the activation of the IFN-l1 gene promoter triggered by 88 bp dsRNA (Fig. 4A) , indicating a positive role for p38a MAPK in RLR/TLR-stimulated gene expression. Overexpression of human p38a MAPK enhanced the activation of the IFN-l1 promoter in a dose-dependent fashion, whereas overexpression of dnp38 decreased the promoter activation (Fig. 4A) , further demonstrating the positive role of p38a MAPK in RLR/ TLR signaling. Especially, the inhibition of IFN-l1 promoter activation by SB202190 and overexpression of dnp38 and the enhancement of promoter activation by overexpression of p38a MAPK were more significant in RIG-I-or MDA5-expressing HEK293 cells (Fig. 4A) , indicating that the regulation of IFN-l1 promoter activation by p38a MAPK is more likely through RLR signaling. SB202190 was also able to inhibit dsRNA-induced activation of IFN-b and IFN-a1 promoters (Fig. 4B) . The positive regulatory role of overexpressed p38a MAPK was more modest on IFN-b and IFN-a1 promoters compared with that of the IFN-l1 promoter, but IFN-b promoter activation was still sensitive to the inhibitory effect by SB202190, and IFN-a1 promoter activation was reduced by overexpression of dnp38 (Fig. 4B) .
We also analyzed dsRNA-induced expression of IFN-l1 in HEK293 cells in the presence of SB202190 or during overexpression of p38a MAPK and dnp38 (Fig. 5A) . Stimulation of HEK293 cells with 88 bp dsRNA led to the induction of endogenous IFN-l1 mRNA expression, and this induction was enhanced with ectopic expression of RIG-I, whereas overexpression of p38a MAPK or dnp38 could not enhance the induction of IFN-l1 mRNA expression (Fig. 5A) . Moreover, co-overexpression of RIG-I and p38a MAPK significantly enhanced the induction of IFN-l1 mRNA expression, whereas co-overexpression of RIG-I and dnp38 decreased the induction of the IFN-l1 mRNA compared with cells that were transfected only with the RIG-Iexpression plasmid (Fig. 5A) . Again, in RIG-I-overexpressing cells, the induction of IFN-l1 mRNA expression by 88 bp dsRNA was inhibited by SB202190 (Fig. 5A) . Western blot analysis showed that the amount of phosphorylated p38 was increased after transfection with 88 bp dsRNA and decreased in dnp38-overexpressing cells (Fig. 5B, 1st row) . Moreover, after 88 bp dsRNA stimulation, the phosphorylation level of IRF3 was increased in RIG-I overexpressing HEK293 cells compared with cells that were not overexpressing RIG-I, and co-overexpression of RIG-I together with p38a MAPK or dnp38 did not affect the phosphorylation of IRF3 compared with RIG-I-overexpressing cells (Fig. 5B, 3rd row) , even though the IFN-l1 mRNA expression level was greatly changed after co-overexpression (Fig.  5A) . It is of interest to note that the amount of total p38 MAPK was increased slightly in HEK293 cells co-overexpressing RIG-I and p38a MAPK or RIG-I and dnp38 (Fig. 5B, 2nd row) , whereas the expression level of IRF3 remained approximately the same in all conditions (Fig. 5B, bottom row) .
ISRE and NF-kB1 sites are essential for p38a MAPK-dependent activation of IFN-l1 gene expression
To investigate further the mechanism how the IFN-l1 gene is activated and regulated by p38a MAPK, we analyzed the role of ISRE and NF-kB promoter elements in the IFN-l1 promoter activation after stimulation by different RNA molecules. To characterize the role of these transcription factor binding sites on IFN-l1 gene activation, different single and double mutations were introduced into the promoter region of IFN-l1 (Fig. 6A) . In RIG-I-overexpressing cells, the WT IFN-l1 promoter was well activated by 88 bp dsRNA, but the activation level was reduced if ISRE and NF-kB1 sites of the promoters were mutated (Fig. 6B) . However, mutations at the NF-kB2 site did not change the level of promoter activation in response to RNA stimulation, suggesting that the NF-kB2 site is not as important in the activation of the IFN-l1 promoter as the NF-kB1 site (Fig. 6B) . Moreover, if both the ISRE and NF-kB1 sites were mutated, the IFN-l1 promoter did not respond to RNA stimulation in RIG-Ioverexpressing cells (Fig. 6B) , suggesting that both of these sites are required for maximal activation of the promoter. Similar results were also found in MDA5-overexpressing HEK cells (Supplemental Fig. 4 ).
To study further the role of the p38a MAPK signaling pathway on ISRE-and NF-kB1-dependent IFN-l1 gene activation, the effect of SB202190 and overexpression of p38a MAPK were analyzed on WT, ISRE, or NF-kB1 mutant IFN-l1 promoter activation. Overexpression of an active form of RIG-I, DRIG-I, as well as MAVS and TRIF activated the WT IFN-l1 promoter, whereas treatment with SB202190 decreased this activation (Fig. 7A, 1st bar chart) . In addition, overexpression of p38a MAPK together with other signaling components (DRIG-I, MAVS, or TRIF) led to clearly enhanced activation of the IFN-l1 promoter. Moreover, mutations at ISRE and NF-kB1 sites on the IFN-l1 promoter resulted in reduced promoter activation and high sensitivity to SB202190 (Fig. 7A, 2nd and 3rd bar charts) . Interestingly, SB202190 treatment and overexpression of p38a MAPK did not affect the activation of the WT IFN-l1 promoter or the promoter containing mutated ISRE or NF-kB1 sites if the cells were stimulated by cotransfection with MyD88 and IRF7 expression constructs (Fig. 7A) .
It has been shown that besides being regulated by IRF3, the human IFN-a1 gene is mainly regulated by IRF7 [39, 51, 52] . To demonstrate further that the IRF7 signaling pathway is not essential for p38a MAPK to regulate the IFN-a1 gene, the activation of the IFN-a1 promoter was measured after stimulation by IRF7 expression or coexpression of IRF7 and MyD88 in the presence or absence of SB202190 or overexpression of p38a MAPK. Consistent with the data above (Fig. 7A) , SB202190 did not inhibit the activation of the IFN-a1 promoter stimulated by expression of IRF7 alone or by coexpression of IRF7 and MyD88 (Fig. 7B ), whereas the protein expression level of MyD88 or IRF7 remained the same (Fig. 7C) . The overexpression of p38a MAPK also failed to enhance the promoter activation effectively under these conditions (Fig. 7B) , whereas overexpression of p38a MAPK reduced the expression of MyD88 or IRF7 proteins to some extent (Fig. 7C) . Altogether, our data suggest that the MyD88-IRF7 pathway is not essential for p38a MAPK to regulate IFN promoter activity.
IRF3/IRF7 and NF-kB are essential for p38a MAPK-dependent regulation of Ifn-b1 gene expression in mouse 3T3 cells
As described previously, IRFs regulate IFN-l1 gene expression, mainly through binding to the ISRE site, whereas the regulation by NF-kB takes place through its binding to cognate NF-kB sites. Having observed that ISRE and NF-kB1 sites at the IFN-l1 promoter are essential for p38a MAPK-dependent activation of IFN-l1 transcription, we further studied the role of IRF3, IRF7, and NF-kB in the regulation of Ifn-b1 gene expression by p38a MAPK in mouse 3T3 cells. As mice lack the human counterpart of IFN-l1, we concentrated on analyzing mouse Ifn-b1 gene expression in IRF3/IRF7 KO and NF-kB KO mouse 3T3 cells. Consistent with the data on IFN-l1 gene expression in HEK293 cells (Fig. 5A) , mouse Ifn-b1 mRNA expression was activated by stimulation with 88 bp dsRNA in WT mouse 3T3 cells, and the activation was weakly enhanced by overexpression of RIG-I or p38a MAPK (Fig. 8A, 1st bar chart) . However, coexpression of RIG-I and p38a MAPK led to a clearly detectable increase in Ifn-b1 mRNA expression. SB202190 efficiently inhibited Ifn-b1 mRNA expression in RIG-I-overexpressing WT 3T3 cells. However, in IRF3/IRF7 KO and NF-kB KO cells, 88 bp dsRNAinduced expression of Ifn-b1 mRNA was decreased significantly compared with the WT mouse 3T3 cells, and coexpression of RIG-I and p38a MAPK failed to enhance the Ifn-b1 mRNA expression (Fig. 8A, 2nd and 3rd bar charts) . This data suggest that IRF3/IRF7 and NF-kB are the key transcription factors that work in concert with p38a MAPK to regulate early IFN gene expression, such as those of mouse Ifn-b and human IFN-l1 genes.
p38a MAPK is involved in the binding of IRF3 and NF-kB to the IFN-l1 promoter
To characterize further the role of the p38a MAPK signaling pathway on regulating the binding of IRF3 and NF-kB to the IFN-l1 promoter, DNA affinity-binding assays were carried out. moDCs were transfected with 88 bp dsRNA in the presence or absence of SB202190, cells were collected at 2 h and 4 h after RNA stimulation, and nuclear proteins were extracted and precipitated by use of the IFN-l1 gene promoter ISRE-and NF-kB1-site oligonucleotides. The binding of phosphorylated IRF3 to the ISRE site and p65 and p50 to the NF-kB1 site was clearly enhanced already at 2 h after RNA stimulation, whereas the presence of SB202190 reduced the binding of both transcription factors, especially at the early stage-2 h after RNA stimulation (Fig. 8B and C) . The regulation of IFN-l1 mRNA expression by p38a MAPK likely occurs via a pathway apart from the TBK1 signaling pathway in human moDCs It is well known that the activation of the TBK1/IKKe complex is essential for phosphorylation and activation of IRF3 [14, 21, 22] . As we clearly show that the activation of IRF3 through RLR signaling and the binding of the phosphorylated IRF3 to ISRE site on the promoter of the IFN-l1 gene are required for the regulation of the IFN-l1 gene by p38a MAPK (Figs. 6, 7A, and 8A  and B) , we wanted to analyze whether the positive regulatory effect of p38 MAPK takes place via the TBK1/IKKe or through another pathway. moDCs were pretreated with increasing doses of the TBK1 inhibitor MRT67307 or with the combination of MRT67307 and SB202190, followed by transfection with 88 bp dsRNA and analysis of the expression of IFN-l1 mRNA at the 4 h time-point after RNA stimulation. The induction of IFN-l1 mRNA expression was inhibited by MRT67307 in a dose-dependent fashion (Fig. 9) . However, in cells pretreated with the combination of MRT67307 and SB202190, IFN-l1 expression was reduced even further when the dose of SB202190 increased, and the dose of MRT67307 remained the same (Fig. 9) . Similar results were observed when the dose of MRT67307 increased, and the SB202190 dose remained constant (Fig. 9) . These data suggest that p38 MAPK regulates IFN-l1 gene expression, not directly through the activation of the TBK1/IKKe complex but through another parallel pathway instead.
DISCUSSION
It is well established that different types of RNAs bind and activate specific members of the TLR and RLR families. This, in turn, leads, via certain adaptor proteins, to the activation of downstream transcription factors, especially those belonging to the IRF and NF-kB families, which play an essential role in IFN gene expression. However, despite the rapid advances in the studies of IFN induction pathways by PRRs, the precise mechanisms by which additional signaling cascades participate in the regulation of IFN gene expression have remained uncharacterized, especially for the regulation of type III IFNs. In the present study, we used several pharmacological signaling inhibitors to identify previously unrecognized signaling pathways that are involved in the regulation of IFN gene expression in human DCs. We found that depending on the size and type of RNAs, PI3K and several MAPK pathways contribute to RNAinduced IFN gene expression ( Fig. 1 and Supplemental Fig. 1 ). Interestingly, the p38 MAPK inhibitors were very efficient in inhibiting IFN gene expression (Figs. 1 and 2A) , and this inhibition took place also in the presence of protein synthesis inhibitor ( Fig. 3 and Supplemental Fig. 3 ), indicating that p38 MAPK is contributing to the very early transcriptional events regulating type I and type III IFN gene expression. Phosphorylation of p38 MAPK increased after 88 bp dsRNA stimulation (Figs. 2B and D and 5B), suggesting that short dsRNA molecules can also activate the p38 MAPK signaling pathway in addition to the classic PRR signaling pathways. Nucleofection of p38a MAPK in dsRNA-stimulated moDCs enhanced IFN-l1 mRNA expression (Fig. 2C) , further demonstrating the positive role of p38 MAPK in IFN-l1 gene regulation. The expression of phosphorylated forms of IRF3 and p38 MAPK was increased after 88 bp dsRNA stimulation ( Fig. 2B and D) , suggesting that these 2 signaling pathways cooperatively regulate the induction of the IFN-l1 gene. In addition, overexpression studies with p38a MAPK, dnp38, and some TLR/RLR family members suggest that the RIG-I and IRF3 pathway, but not the MyD88 and IRF7 pathway, is required for the regulation of IFN gene expression by p38a MAPK (Figs. 4, 5,  and 7) . Moreover, the effects of mutations in the IFN-l1 promoter (Figs. 6 and 7) , DNA affinity-binding experiments in human moDCs (Fig. 8B) , and experiments in mouse IRF3/IRF7 and NF-kB KO cells (Fig. 8A) suggest that the IRF and NF-kB transcription factors and their respective binding sites ISRE and NF-kB1 in the IFN-l1 promoter are essential in RNA-regulated IFN gene expression. Furthermore, in these experiments, p38a MAPK had a positive regulatory role (Figs. 7 and 8 ). In addition, the inhibitor-combination experiments in human moDCs suggest that the regulation of IFN-l1 mRNA expression by p38a MAPK does not take place directly through activation of the TBK1/IKKe complex (Fig. 9) , and Western blot analysis also showed that the addition of inhibitors of p38 MAPK and overexpression of p38a MAPK or dnp38 could not significantly affect the phosphorylation of IRF3 (Figs. 2B and D and 5B), further suggesting that p38 MAPK regulates IFN-l1 gene expression, not directly through activation of IRF3. Therefore, our data strongly indicate that p38a MAPK positively regulates early IFN-l1 gene expression by cooperating with the transcription factors IRF3 and NF-kB through some parallel signaling pathway after RNA stimulation (Fig. 10) .
It has been shown previously that p38 MAPK plays a central role in inflammatory responses induced by environmental stress, growth factors, and inflammatory factors [53] [54] [55] . Furthermore, the p38 MAPK signaling pathway was shown to be involved in IFN signaling and regulation of antiviral responses [34] . However, less is known about the role of p38 MAPK in regulating IFN gene expression. It has been reported that the activation of RIG-I during Sendai virus infection leads to the activation of p38 MAPK, which contributes to type I IFN-mediated antiviral responses and the activation of conventional DCs [56] . It has also been found that 2 p38a MAPKAPKs-MAPKAPK2 and MAPKAPK3-regulate the expression of IFN-inducible genes and antiviral responses [35] . The present study demonstrates that besides the regulation of IFN signaling and antiviral response [34, 35, 56] , p38 MAPK is activated by short dsRNA stimulation (Figs. 2B and D and 5B) and is taking part in the regulation of RNA-induced early IFN gene expression in human moDCs, especially those of IFN-l1 and IFN-b genes (Figs. 1 and 2 and Supplemental Figs. 1 and 2 ). Our data are also consistent with a previous study, which showed that in human macrophages, IFN induction by the infection with an RNA virus-IAV-is predominantly regulated by IRF3 and p38 MAPK [57] . The PI3K inhibitor also decreased the expression of the IFN-l1 gene, especially in response to stimulation with short 88 nt ssRNA and long 1.8 kb dsRNA molecules (Fig. 1) , suggesting some selectivity of the PI3K pathway in RNA-induced innate immune response. However, further studies are needed to elucidate the potential role of these pathways in regulating IFN gene expression.
To investigate further the mechanism by which p38 MAPK regulates the expression of the IFN gene in response to RNA stimulation, the relationship of different RNA receptors was studied. Overexpression of p38a or dnp38 MAPK regulated the activation of the IFN-l1 promoter positively or negatively, respectively, through RLR (RIG-I and MDA5) and TLR (TLR3) pathways (Fig. 4A) , indicating a broader role for p38a MAPK in intracellular signaling. Moreover, co-overexpression of RIG-I and p38a MAPK enhanced the IFN-l1 promoter activity at higher levels compared with IFN-b and IFN-a1 promoters (Fig. 4B) , suggesting that the promoter of type III IFN genes can be regulated by a broader scale of transcription factors than type I IFN genes. Even though the precise site of action of p38a MAPK Figure 9 . The role of the p38 MAPK inhibitor and TBK1 inhibitor on regulating IFN-l1 mRNA expression in short dsRNA-stimulated human moDCs. moDCs from 4 different blood donors were grown separately on 24-well plates. Cells remained untreated or were pretreated with an indicated amount of p38 MAPK inhibitor SB202190 or TBK1 inhibitor MRT67307 (MRT), 0.5 h before transfection with 88 bp dsRNA (50 ng/ml). Cells were collected 4 h after RNA transfection, and total cellular RNA was isolated, and IFN-l1 remains partially unresolved, we were able to show that p38a MAPK is activated by RNA stimulation, and it works in concert with RIG-I/MDA5-MAVS-IRF3 signaling without directly activating the TBK1/IKKe complex. This suggests that p38a MAPK enhances IFN gene transcription via a pathway apart from but in cooperation with IRF3 and NF-kB, the key transcription factors regulated by all RNA sensors (Fig. 10) .
As our results indicated that p38a MAPK was regulating IFN-l1 gene expression downstream of the RNA sensors, we studied the functionality of the IFN-l1 promoter by creating IRF and NF-kB binding-site mutations to the promoter (Fig. 6A) . We demonstrated that ISRE and NF-kB1 sites in the IFN-l1 promoter are indispensable for the activation of the promoter (Fig. 6B) . Although there are also other important transcription-factor binding sites on the IFN-l1 promoter, such as the PRDI site, and also 4 distal NF-kB binding sites far away from the start coding site [58] , mutations targeting ISRE and NF-kB1 sites were able to abolish completely the activation of the IFN-l1 promoter (Fig.  6B) , suggesting that these 2 sites play an essential role in regulating IFN-l1 promoter activity. Furthermore, these 2 promoter sites were required for the p38a MAPK-mediated positive regulatory effect on IFN-l1 promoter activity (Fig. 7A) . Moreover, the DNA affinity-binding experiments showed that SB202190 can reduce the transcriptional activation of IRF3 and the active subunits of NF-kB (p65 and p50) on the IFN-l1 promoter (Fig. 8) . This suggests that p38a MAPK together with IRF3 and NF-kB transcription factors contributed to RNAstimulated induction of the IFN-l1 gene. However, Western blot analysis did not show any specific phospho-p38, total p38, phospho-ATF2, or total ATF2 bands after precipitation with ISRE and NF-kB oligonucleotides in the DNA affinity-binding assay, and mutations on putative binding sites of p38-regulated transcription factors (ATF2, CREB, and p53) on the IFN-l1 promoter failed to reduce the promoter activity (data not shown), suggesting that p38 MAPK regulates IFN-l1 gene expression via another mechanism rather than enhancing the binding of these p38-regulated transcription factors on the IFN-l1 promoter. Further experiments in mouse IRF3/IRF7 or NF-kB KO 3T3 cells demonstrated the importance of IRFs and NF-kB in the regulation of Ifn gene expression by p38a MAPK (Fig. 8A) . Our data are consistent with the study of Dr. Peiris and coworkers [57] , who reported that both IRF3 and p38 MAPK function in enhancing cytokine production in H5N1 influenza virus-infected cells. Moreover, the same authors showed that the p38 MAPK inhibitor (SB203580) did not affect the nuclear translocation of IRF3. Accordingly, our data also showed that p38 MAPK inhibitors (SB203580 and SB202190) failed to decrease the phosphorylation of IRF3 after 88 bp dsRNA stimulation (Fig. 2B) . This may suggest that p38 MAPK cooperatively regulates IFN gene expression only after the phosphorylation and translocation of IRF3. Therefore, in our experimental approaches, we monitored IFN mRNA expression and used the IFN-l1 promoterreporter construct, as well as 2 specific p38 MAPK inhibitors, to demonstrate the cooperability of p38a MAPK with IRF3 and NF-kB.
It was of interest to note that p38a MAPK did not regulate IFNl1 gene expression via the MyD88-IRF7 pathway (Fig. 7A) . In addition, p38a MAPK failed to enhance IRF7 or MyD88-IRF7-dependent activation of the IFN-a1 promoter in transfected HEK293 cells (Fig. 7B) . As IRF7 is the key transcription factor regulating late IFN genes (almost all IFN-a subtypes), this data suggest that p38a MAPK mainly regulates the expression of early IFN genes (IFN-l1 and IFN-b) in cooperation with IRF3 or NF-kB transcription factors. Indeed, early RIG-I -mediated promoter activities of human IFN-l1, IFN-b, and IFN-a1 were inhibited by SB202190 and enhanced by p38a MAPK overexpression (Fig. 4B) . Furthermore, RNA-induced IFN-l1 or IFN-a1 expression was inhibited by SB202190, also in the presence of protein synthesis inhibitor CHX, indicating that the regulation of IFN mRNA expression by p38 MAPK takes place directly after RNA stimulation and does not require de novo protein synthesis. Our data are also consistent with the study of Dr. Ludwig and coworkers [59] , who reported that inhibition of p38 MAPK by the p38-specific inhibitor SB202190 led to reduced expression of IFN-b and other cytokines in H5N1 and H7N7 virus-infected cells. The studies by us and others indicate a clear role of p38 MAPK in regulating IFN gene expression at early stages of RNA stimulation or viral infection.
Our data, as concluded from multiple experimental approaches, strongly suggest that p38a MAPK, together with IRF3 and NF-kB, regulates the expression of early IFN genes, especially that of the type III IFN-l1 gene. This suggests that p38 MAPK is not only involved in IFN signaling and induction of an antiviral response, but it also contributes to transcriptional regulation of IFN genes in RNA-stimulated cells. Our study thus provides new mechanistic evidence for the function of p38a MAPK in the early antiviral signaling pathways and provides further evidence for the complexity of signal transduction pathways and the fine-tuning of IFN responses. AUTHORSHIP M.J. designed the study, performed laboratory experiments, analyzed the results, and wrote the paper. P.Ö. and I.J. designed the study and wrote the paper. R.F. performed laboratory experiments. D.N.R. performed laboratory experiments and wrote the paper. A.H., M.M.P., and D.H.B wrote the paper.
